CSGALNACT2抗体

The CSGALNACT2 antibody targets the chondroitin sulfate N-acetylgalactosaminyltransferase 2 (CSGALNACT2), a key enzyme in the biosynthesis of chondroitin sulfate (CS), a sulfated glycosaminoglycan (GAG) critical for extracellular matrix structure and cellular signaling. CSGALNACT2 catalyzes the transfer of N-acetylgalactosamine (GalNAc) to glucuronic acid residues during CS chain elongation, influencing the sulfation patterns and functional diversity of CS proteoglycans. These proteoglycans play roles in tissue development, neuronal plasticity, and inflammatory responses. Dysregulation of CSGALNACT2 has been implicated in pathological conditions, including cancer progression, cartilage disorders, and neurodegenerative diseases. Antibodies against CSGALNACT2 are essential tools for studying its expression, localization, and function in both normal and diseased tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding research into CS biosynthesis mechanisms and potential therapeutic targeting. Recent studies highlight its association with tumor invasiveness and metastasis, suggesting CSGALNACT2 as a biomarker or therapeutic candidate. However, its tissue-specific roles and regulatory pathways remain under investigation, necessitating further validation of antibody specificity and functional studies to clarify its contributions to health and disease.